Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Arzoxifene vs Tamoxifen in Advanced or Metastatic Breast Cancer
NCT00034125Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Modality
- Small Molecules
- Countries
- 5
01
Overview
Phase 3, randomised, double-blind trial of arzoxifene in breast cancer (2 arms), sponsored by Eli Lilly and Company. Primary endpoint: Progression-Free Survival. Status: completed.
02
Drugs
arzoxifene
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00034125.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00034125.